UBS lowered the firm’s price target on Kura Oncology (KURA) to $14 from $27 and keeps a Buy rating on the shares. Kura reported Q4 earnings and provided pipeline estimates, and said it recently entered into a licensing agreement with Kyowa Kirin for lead program ziftomenib with 50/50 U.S. sales and 15% royalty on ex-U.S. sales, the analyst tells investors in a research note. Despite recent stock weakness, the firm continues to see zifto as a promising menin inhibitor in Acute Myeloid Leukemia.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology’s Financial Future at Risk: Dependency on Kyowa Kirin for Ziftomenib Development Raises Concerns
- Kura Oncology’s Positive Earnings Call Highlights Progress and Prospects
- Kura Oncology: Strong Financials and Promising Clinical Developments Drive Buy Rating
- Bullish Outlook for Kura Oncology: Buy Rating Affirmed Amid Optimism for Ziftomenib Approval and Competitive Advantage
- Kura Oncology’s Promising Pipeline and Strategic Focus Justify Buy Rating
Questions or Comments about the article? Write to editor@tipranks.com